Danaher Corporation DHR

What the company does

Danaher Corporation is a large-cap company in the Healthcare sector (Diagnostics & Research), with a market value of $162.0B, based in the USA.

It employs about 58,000 people and has been listed since Jan 05, 1979.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.

Cheap or expensive? priced in line with its group

Its price-to-earnings (P/E) is 38.2 versus 36.9 for the median of the Healthcare sector in our universe (25 companies) — priced in line with its group.

Revenue is growing 8% versus the same quarter last year.

On analysts' next-year forecasts the multiple drops to 23.8 — they expect higher earnings.

The average analyst price target is 259.19, 12% above the current price (their view, not ours).

The stock sits at 87% of its one-year range (0% = the low, 100% = the high).

The risks

• No risk flags were detected from the data we have.

Strengths

• ✅ Profitable — 19 of every 100 dollars of revenue stays as profit.
• ✅ Generates free cash flow — profit becomes cash in the bank.
• ✅ Buys back its shares (1% fewer shares in a year).
• ✅ Most analysts rate it buy (20 vs 0).
• ✅ Pays a dividend (0.7% a year).

What changed this week

Over the past week the stock rose 0.6% (for comparison: S&P 500 -0.4%, sector ETF XLV +1.4%).

The company published its quarterly report this week — see the plain-language summary above.

This week's news

• GE HealthCare Technologies (GEHC) vs. DHR and MDT: Can a $23.9B Backlog and AI Innovation Drive a Healthcare Re-Rating? finance.yahoo.com · 2026-10-22
  What the article says

  Is GEHC a good stock to buy? We came across a bullish thesis on GE HealthCare Technologies Inc. on Astute Optics - US's Substack. The thesis was published on September 13th, when the stock was trading at $64.25, and GEHC gained 9.30% since then. The gain appears to reflect improving sentiment toward healthcare stocks… source ↗

• What Does Danaher (DHR) FDA Clearance For AI AFib Detection Mean Now? finance.yahoo.com · 2026-10-22
  What the article says

  Danaher (NYSE:DHR) subsidiary Masimo received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable monitor. The approved system uses artificial intelligence to identify potential AFib episodes in patients using Masimo's hospital-grade wireless device. The AFib detection feature is… source ↗

• LH vs. DHR: Which Stock Is the Better Value Option? finance.yahoo.com · 2026-10-22
  What the article says

  Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a strong… source ↗

• Danaher (DHR) Q3 Earnings Fuel Stock Gains On Margin Expansion finance.yahoo.com · 2026-10-22
  What the article says

  Danaher came into this Q3 2026 report with the stock already grinding higher over the past three months. It then jumped another 4.3% to about $233.86 after the release. The move looks like a relief rally, yet the core story sits in the income statement. Management delivered roughly $6.6b of revenue and pushed adjusted… source ↗

• Company News for Oct 22, 2026 finance.yahoo.com · 2026-10-22
  What the article says

  Capital One Financial Corp.'s (COF) shares gained 2.5% after the company reported third-quarter 2026 adjusted earnings of $6.69 per share, surpassing the Zacks Consensus Estimate of $5.45 per share. Shares of Bank OZK (OZK) surged 4.2% after the company posted third-quarter 2026 adjusted earnings of $1.50 per share,… source ↗

• DHR Q3 deep dive: execution focus and AI strategy underpin improved outlook finance.yahoo.com · 2026-10-22
  What the article says

  DHR Q3 deep dive: execution focus and AI strategy underpin improved outlook Diversified science and technology company Danaher (NYSE:DHR) met Wall Street's revenue expectations in Q3 2026, with sales up 8.3% year on year to $6.55 billion. Its non-GAAP profit of $2.11 per share was 10% above analysts' consensus… source ↗

What changed since last week

• Risk flag cleared: earnings report coming up.

• The average analyst target moved from 244.14 to 259.19.

• A new quarterly report was published (quarter ended Sep 30, 2026).